Hai-Tsang Huang

This inventor holds 7 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hai-Tsang Huang. Retrieved from https://idiyas.com/inventor/hai-tsang-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 71.4

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 16(Granted Patents)

Company Filing History:

7 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

Years Active: 2020-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12329821 - Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use (2025-06-17),

2. 11730818 - Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use (2023-08-22),

3. 10925967 - Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use (2021-02-23),

4. 10925868 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use (2021-02-23),

5. 10875844 - Salicylate inhibitors of MELK and methods of use (2020-12-29),

6. 10842878 - Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use (2020-11-24),

7. 10544138 - Tricyclic kinase inhibitors of MELK and methods of use (2020-01-28),

Title: **Hai-Tsang Huang: Innovator in Biotechnology**

Introduction

Hai-Tsang Huang is a prominent inventor based in Boston, MA, renowned for his contributions to the field of biotechnology. With a remarkable portfolio of seven patents, his work primarily focuses on advancing therapeutic strategies through innovative methods that target proteins involved in various diseases.

Latest Patents

Among Hai-Tsang Huang's latest patents is a significant innovation pertaining to the degradation of Bruton's tyrosine kinase (BTK) by conjugating BTK inhibitors with E3 ligase ligands. This patent details the development of bifunctional compounds that facilitate targeted degradation of BTK, employing a unique approach that links a ubiquitin ligase-binding moiety to a ligand capable of binding to BTK. Such innovations are poised to enhance treatment options for disorders regulated by BTK, offering new hope in therapeutic interventions.

Career Highlights

Hai-Tsang Huang's career is marked by his impactful research at the Dana-Farber Cancer Institute Inc., where he has been integral to advancing cancer treatment methodologies. His pioneering work continues to shape the landscape of biochemical research, reinforcing the importance of targeted therapies in modern medicine.

Collaborations

Throughout his career, Huang has collaborated with esteemed colleagues, including Nathanael Schiander Gray and Dennis Dobrovolsky. Their combined expertise fosters an environment of innovation, contributing to breakthroughs in the understanding and treatment of cancer and other diseases influenced by BTK.

Conclusion

Hai-Tsang Huang stands as an influential figure in biotechnology, driving forward research that bridges the gap between innovation and practical application in medicine. His patents represent significant strides in treating diseases, showcasing the power of targeted therapies and collaborations within the scientific community.

Profile summary based on public USPTO records.